We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Underperforming Diabetes Drugs Impede Merck Restructuring Plans
Despite attempts to pad its patent cliff fall with a massive R&D restructuring plan, Merck is still hurting in large part due to poor sales of its blockbuster diabetes franchise for Januvia and Janumet in the U.S.